Cargando…

Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer

Aiming to address the issue of poor bioavailability of most anti-tumor medicines against colorectal cancer, we developed a targeted anticancer nanocarrier using biocarriers able to both bind and easily release their load in a controlled manner. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) carriers w...

Descripción completa

Detalles Bibliográficos
Autores principales: Radu, Ionut Cristian, Hudita, Ariana, Zaharia, Catalin, Galateanu, Bianca, Iovu, Horia, Tanasa, Eugenia (Vasile), Georgiana Nitu, Sabina, Ginghina, Octav, Negrei, Carolina, Tsatsakis, Aristidis, Velonia, Kelly, Shtilman, Mikhail, Costache, Marieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442118/
https://www.ncbi.nlm.nih.gov/pubmed/30896267
http://dx.doi.org/10.1080/10717544.2019.1582729
_version_ 1783407650102312960
author Radu, Ionut Cristian
Hudita, Ariana
Zaharia, Catalin
Galateanu, Bianca
Iovu, Horia
Tanasa, Eugenia (Vasile)
Georgiana Nitu, Sabina
Ginghina, Octav
Negrei, Carolina
Tsatsakis, Aristidis
Velonia, Kelly
Shtilman, Mikhail
Costache, Marieta
author_facet Radu, Ionut Cristian
Hudita, Ariana
Zaharia, Catalin
Galateanu, Bianca
Iovu, Horia
Tanasa, Eugenia (Vasile)
Georgiana Nitu, Sabina
Ginghina, Octav
Negrei, Carolina
Tsatsakis, Aristidis
Velonia, Kelly
Shtilman, Mikhail
Costache, Marieta
author_sort Radu, Ionut Cristian
collection PubMed
description Aiming to address the issue of poor bioavailability of most anti-tumor medicines against colorectal cancer, we developed a targeted anticancer nanocarrier using biocarriers able to both bind and easily release their load in a controlled manner. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) carriers were obtained via the emulsification-diffusion method, loaded with 5-fluorouracil and then characterized in terms of particle morphology and size (SEM, DLS), drug uptake and release. The cytotoxic potential of the 5-fluorouracil-loaded polymer nanocarriers on human adenocarcinoma cells (HT-29 cell line) was investigated. The in vitro studies clearly demonstrated that while the nanocarriers themselves slightly alter HT-29 cell viability, when loaded with 5-fluorouracil they significantly decrease cell viability, suggesting that the polymer itself exhibits low cytotoxicity and the drug-loaded carrier acts in an efficient manner to kill HT-29 human adenocarcinoma cells.
format Online
Article
Text
id pubmed-6442118
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-64421182019-04-05 Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer Radu, Ionut Cristian Hudita, Ariana Zaharia, Catalin Galateanu, Bianca Iovu, Horia Tanasa, Eugenia (Vasile) Georgiana Nitu, Sabina Ginghina, Octav Negrei, Carolina Tsatsakis, Aristidis Velonia, Kelly Shtilman, Mikhail Costache, Marieta Drug Deliv Research Article Aiming to address the issue of poor bioavailability of most anti-tumor medicines against colorectal cancer, we developed a targeted anticancer nanocarrier using biocarriers able to both bind and easily release their load in a controlled manner. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) carriers were obtained via the emulsification-diffusion method, loaded with 5-fluorouracil and then characterized in terms of particle morphology and size (SEM, DLS), drug uptake and release. The cytotoxic potential of the 5-fluorouracil-loaded polymer nanocarriers on human adenocarcinoma cells (HT-29 cell line) was investigated. The in vitro studies clearly demonstrated that while the nanocarriers themselves slightly alter HT-29 cell viability, when loaded with 5-fluorouracil they significantly decrease cell viability, suggesting that the polymer itself exhibits low cytotoxicity and the drug-loaded carrier acts in an efficient manner to kill HT-29 human adenocarcinoma cells. Taylor & Francis 2019-03-21 /pmc/articles/PMC6442118/ /pubmed/30896267 http://dx.doi.org/10.1080/10717544.2019.1582729 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Radu, Ionut Cristian
Hudita, Ariana
Zaharia, Catalin
Galateanu, Bianca
Iovu, Horia
Tanasa, Eugenia (Vasile)
Georgiana Nitu, Sabina
Ginghina, Octav
Negrei, Carolina
Tsatsakis, Aristidis
Velonia, Kelly
Shtilman, Mikhail
Costache, Marieta
Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer
title Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer
title_full Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer
title_fullStr Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer
title_full_unstemmed Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer
title_short Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer
title_sort poly(3-hydroxybutyrate-co-3-hydroxyvalerate) phbhv biocompatible nanocarriers for 5-fu delivery targeting colorectal cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442118/
https://www.ncbi.nlm.nih.gov/pubmed/30896267
http://dx.doi.org/10.1080/10717544.2019.1582729
work_keys_str_mv AT raduionutcristian poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT huditaariana poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT zahariacatalin poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT galateanubianca poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT iovuhoria poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT tanasaeugeniavasile poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT georgiananitusabina poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT ginghinaoctav poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT negreicarolina poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT tsatsakisaristidis poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT veloniakelly poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT shtilmanmikhail poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer
AT costachemarieta poly3hydroxybutyrateco3hydroxyvaleratephbhvbiocompatiblenanocarriersfor5fudeliverytargetingcolorectalcancer